发明公开
- 专利标题： BROMODOMAIN INHIBITORS
-
申请号： US17810313申请日： 2022-06-30
-
公开(公告)号： US20230158039A1公开(公告)日： 2023-05-25
- 发明人: Le Wang , John K. Pratt , Keith F. McDaniel , Yujia Dai , Steven D. Fidanze , Lisa Hasvold , James H. Holms , Warren M. Kati , Dachun Liu , Robert A. Mantei , William J. McClellan , George S. Sheppard , Carol K. Wada
- 申请人： AbbVie Inc.
- 申请人地址： US IL North Chicago
- 专利权人： AbbVie Inc.
- 当前专利权人： AbbVie Inc.
- 当前专利权人地址： US IL North Chicago
- 分案原申请号： US13828285 2013.03.14
- 主分类号： A61K31/541
- IPC分类号： A61K31/541 ; C07D487/04 ; C07D471/04 ; A61K31/437 ; A61K31/5025 ; A61K31/5377 ; A61K45/06
摘要：
The present invention provides for compounds of formula (I)
wherein A1, A2, A3, A4, X1, X2, Y1, L1, G1, Rx, and Ry have any of the values defined thereof in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).
wherein A1, A2, A3, A4, X1, X2, Y1, L1, G1, Rx, and Ry have any of the values defined thereof in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).
信息查询
